寡转移性前列腺癌管理的新见解:一项综合综述
本综述检索PubMed近20年文献及ClinicalTrials.gov,汇总寡转移性前列腺癌的转移灶导向治疗(MDT)与前列腺靶向治疗证据,并区分同步与异时转移。作者指出,尽管ADT联合多西他赛或阿比特龙仍是转移性前列腺癌的主要治疗,但寡转移患者接受转移灶和前列腺靶向治疗可能改善结局,并可能延迟全身治疗的使用。
要点
- ADT联合多西他赛或阿比特龙仍是转移性前列腺癌的主要治疗。
- 在寡复发患者中,早期发现并积极治疗转移灶(手术或放疗)似乎是可行策略,可能延迟全身治疗。
- MDT在寡转移性前列腺癌中是有前景的选择,但需要更可靠的数据。
核心结论
- 数据提示,尽管ADT联合多西他赛或阿比特龙仍是转移性前列腺癌的主要治疗,但在寡转移性前列腺癌中,转移灶和前列腺靶向治疗可能改善结局。
- 在寡复发疾病患者中,早期发现和积极治疗转移灶(手术或放疗)似乎是可行策略,并可能延迟全身治疗的使用。
- MDT是寡转移性前列腺癌患者中有前景的选择,但需要更可靠的数据。
- 在同步寡转移性疾病中,积极的减瘤治疗需要进一步数据以确认获益。
- 本综述纳入的研究主要为回顾性,限制了其提供的证据强度;前瞻性研究正在进行中,其结果备受期待。
研究设计与样本
- 本综述检索PubMed中近20年发表的「前列腺癌」与「寡转移」「孤立转移」「立体定向体部放疗」「立体定向消融放疗」「挽救性淋巴结清扫」或「转移灶切除术」的组合文献,并检索ClinicalTrials.gov以识别相关正在进行的试验。
- 研究按转移时间分为同步(即原发性前列腺癌诊断时检测到)和异时(即在原发肿瘤治疗后检测到),并按治疗方式分为MDT(包括挽救性淋巴结清扫[sLND])和前列腺靶向治疗。
- 对于同步/异时转移的MDT,纳入16项已完成研究和11项正在进行的回顾性研究。
- 对于根治性原发治疗后仅淋巴结复发的sLND,纳入11项已完成研究。
- 对于同步转移性前列腺癌的前列腺靶向治疗,纳入25项已完成研究和11项正在进行的回顾性研究。
主要发现
- 在寡复发疾病患者中,早期检测和积极治疗转移灶(手术或放疗)似乎是可行策略,并可能延迟全身治疗的使用。
- MDT在寡转移性前列腺癌患者中是有前景的选择,但需要更可靠的数据。
- 在同步寡转移性疾病中,积极的减瘤治疗需要进一步数据以确认获益。
- 本综述纳入的研究主要为回顾性,限制了其提供的证据强度。
关键数值与推荐
- 当前转移性前列腺癌的标准治疗是雄激素剥夺治疗(ADT)联合多西他赛或阿比特龙。
- 对于同步/异时转移的MDT,纳入16项已完成研究和11项正在进行的回顾性研究。
- 对于根治性原发治疗后仅淋巴结复发的sLND,纳入11项已完成研究。
- 对于同步转移性前列腺癌的前列腺靶向治疗,纳入25项已完成研究和11项正在进行的回顾性研究。
临床怎么用
- 作者指出,ADT联合多西他赛或阿比特龙应继续作为标准治疗。
- 作者认为,有证据表明针对转移灶和原发肿瘤的治疗可能改善患者结局,并可能延迟全身治疗的使用。
- 作者认为,在寡复发疾病患者中,早期检测和积极治疗转移灶(手术或放疗)似乎是可行策略。
- 作者认为,MDT是寡转移性前列腺癌患者中有前景的选择,但需要更可靠的数据。
- 作者认为,在同步寡转移性疾病中,积极的减瘤治疗需要进一步数据以确认获益。
局限性
- 本综述纳入的研究主要为回顾性,限制了其提供的证据强度。
- 前瞻性研究正在进行中,其结果备受期待。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The current standard of care for metastatic prostate cancer (PCa) is androgen deprivation therapy (ADT) plus either docetaxel or abiraterone. Growing evidence suggests that metastasis-directed therapy (MDT) and/or local therapy targeted to the primary tumour (ie, prostate) may be of benefit in the setting of oligometastatic disease. Several prospective studies are underway; however, until robust evidence is available to guide treatment decisions, physicians are challenged with how best to manage patients with oligometastases. OBJECTIVE: This comprehensive review aims to collate the available evidence to date for a role of MDT and/or prostate-targeted therapy in the setting of oligometastatic PCa, as well as discuss ongoing trials in this setting. EVIDENCE ACQUISITION: We searched PubMed for the combination of "prostate cancer" and "oligometastatic", "oligometastases", "oligometastasis", "solitary metastases", "stereotactic body radiotherapy", "SBRT", "stereotactic ablative radiotherapy", "SABR", "salvage lymphadenectomy", or "metastasectomy" in publications over the last 20yr. We also searched ClinicalTrials.gov to identify relevant ongoing trials. EVIDENCE SYNTHESIS: The studies were divided according to the timing of metastasis into synchronous (ie, detected at the time of primary PCa diagnosis) and metachronous (ie, detected after treatment of the primary tumour), and according to treatment modality into MDT (including salvage lymph node dissection [sLND]) and prostate-targeted treatment. For MDT of synchronous/metachronous metastases, we included 16 completed studies and 11 ongoing prospective studies. In the case of sLND for nodal-only recurrence after primary treatment with curative intent, we included 11 completed studies. Finally, for prostate-targeted treatment of synchronous metastatic PCa, we included 25 completed studies and 11 ongoing prospective studies. In selected patients with oligorecurrent disease, early detection and aggressive treatment of metastatic lesions (surgery or radiotherapy) appears to be a feasible strategy and may delay the use of systemic therapies. MDT is a promising option in oligometastatic PCa patients, but more robust data are needed. In the setting of synchronous oligometastatic disease, aggressive cytoreductive treatment needs further data to confirm the benefits. CONCLUSIONS: In this review, we provide a comprehensive overview of the current literature on the treatment of patients with oligometastatic PCa. The data suggest that although ADT plus either docetaxel or abiraterone remains the mainstay of treatment for mPCa, in oligometastatic PCa, improved outcomes may be achieved with metastasis- and prostate-targeted therapies. The studies included in this review are mainly retrospective in nature, limiting the strength of the evidence they provide. Prospective studies are ongoing, and their results are eagerly awaited. PATIENT SUMMARY: We reviewed the treatment of patients with prostate cancer that has spread to five sites or fewer. We conclude that while androgen deprivation plus either docetaxel or abiraterone should remain the standard of care, there is evidence that treatment targeted at the metastases and the primary tumour may improve the outcome for the patient and potentially delay the use of systemic treatment.
引用
- Battaglia A, De Meerleer G, Tosco L, et al. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review. Eur Urol Oncol. 2018. PMID: 31017094. doi:10.1016/j.euo.2018.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。